Sionna net loss widens 65.43% to $29.89 million in Q2 FY26

Reuters2026/08/06 11:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sionna Therapeutics posted a Q2 net loss of USD 29.9 million, widening from USD 18.1 million a year earlier.
RD expense climbed to USD 21.9 million from USD 15.4 million, driven by pipeline development spending and higher personnel costs.
GA costs rose to USD 10.6 million from USD 6.5 million, mainly on higher personnel-related expenses including stock-based compensation.
Cash, cash equivalents and marketable securities totaled USD 268.3 million at June 30, with funding expected to last into 2028.
PreciSION CF Phase 2a trial of SION-719 and a Phase 1 dual-combination study of SION-451 both remain on track for topline data in summer 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sionna net loss widens 65.43% to $29.89 million in Q2 FY26

You may also like

Crypto prices